HUP0400255A2 - Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer - Google Patents
Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancerInfo
- Publication number
- HUP0400255A2 HUP0400255A2 HU0400255A HUP0400255A HUP0400255A2 HU P0400255 A2 HUP0400255 A2 HU P0400255A2 HU 0400255 A HU0400255 A HU 0400255A HU P0400255 A HUP0400255 A HU P0400255A HU P0400255 A2 HUP0400255 A2 HU P0400255A2
- Authority
- HU
- Hungary
- Prior art keywords
- cancer
- treatment
- cytotoxic agents
- receptor ligands
- selected cytotoxic
- Prior art date
Links
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 239000002254 cytotoxic agent Substances 0.000 title abstract 3
- 231100000599 cytotoxic agent Toxicity 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 102000027483 retinoid hormone receptors Human genes 0.000 title 1
- 108091008679 retinoid hormone receptors Proteins 0.000 title 1
- 239000011885 synergistic combination Substances 0.000 title 1
- 102000003702 retinoic acid receptors Human genes 0.000 abstract 2
- 108090000064 retinoic acid receptors Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A találmány kiválasztott citotoxikus szerek és a/< retinoin savreceptor szelektív agonisták vagy retinoinsav receptor panantagonisták kemoterápiás kombinációit, rák kezelésében és akiválasztott citotoxikus szer hatékony citotoxikus dózisánakcsökkentésére való alkalmazásra biztosítja. ÓThe invention provides chemotherapeutic combinations of selected cytotoxic agents and retinoic acid receptor selective agonists or retinoic acid receptor panantagonists for use in the treatment of cancer and for reducing the effective cytotoxic dose of the selected cytotoxic agent. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27775401P | 2001-03-22 | 2001-03-22 | |
| PCT/US2002/008718 WO2002078620A2 (en) | 2001-03-22 | 2002-03-22 | Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0400255A2 true HUP0400255A2 (en) | 2004-08-30 |
Family
ID=23062213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400255A HUP0400255A2 (en) | 2001-03-22 | 2002-03-22 | Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1383491A2 (en) |
| JP (1) | JP2004528316A (en) |
| KR (1) | KR20030086314A (en) |
| CN (1) | CN1498105A (en) |
| BR (1) | BR0207681A (en) |
| CA (1) | CA2441335A1 (en) |
| CZ (1) | CZ20032540A3 (en) |
| DE (1) | DE02733871T1 (en) |
| ES (1) | ES2214985T1 (en) |
| HU (1) | HUP0400255A2 (en) |
| IL (1) | IL157358A0 (en) |
| MX (1) | MXPA03008403A (en) |
| PL (1) | PL368946A1 (en) |
| TR (1) | TR200400812T3 (en) |
| WO (1) | WO2002078620A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007108272A1 (en) * | 2006-03-23 | 2007-09-27 | Tmrc Co., Ltd. | Kit for cancer therapy and pharmaceutical composition for cancer therapy |
-
2002
- 2002-03-22 BR BR0207681-0A patent/BR0207681A/en not_active Application Discontinuation
- 2002-03-22 DE DE0001383491T patent/DE02733871T1/en active Pending
- 2002-03-22 CZ CZ20032540A patent/CZ20032540A3/en unknown
- 2002-03-22 HU HU0400255A patent/HUP0400255A2/en unknown
- 2002-03-22 IL IL15735802A patent/IL157358A0/en unknown
- 2002-03-22 EP EP02733871A patent/EP1383491A2/en not_active Withdrawn
- 2002-03-22 CA CA002441335A patent/CA2441335A1/en not_active Abandoned
- 2002-03-22 JP JP2002576888A patent/JP2004528316A/en not_active Withdrawn
- 2002-03-22 TR TR2004/00812T patent/TR200400812T3/en unknown
- 2002-03-22 WO PCT/US2002/008718 patent/WO2002078620A2/en not_active Application Discontinuation
- 2002-03-22 MX MXPA03008403A patent/MXPA03008403A/en unknown
- 2002-03-22 KR KR10-2003-7012217A patent/KR20030086314A/en not_active Application Discontinuation
- 2002-03-22 PL PL02368946A patent/PL368946A1/en not_active Application Discontinuation
- 2002-03-22 ES ES02733871T patent/ES2214985T1/en active Pending
- 2002-03-22 CN CNA028070011A patent/CN1498105A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TR200400812T3 (en) | 2004-07-21 |
| EP1383491A2 (en) | 2004-01-28 |
| PL368946A1 (en) | 2005-04-04 |
| ES2214985T1 (en) | 2004-10-01 |
| CN1498105A (en) | 2004-05-19 |
| JP2004528316A (en) | 2004-09-16 |
| WO2002078620A2 (en) | 2002-10-10 |
| BR0207681A (en) | 2004-07-27 |
| CA2441335A1 (en) | 2002-10-10 |
| DE02733871T1 (en) | 2004-08-26 |
| KR20030086314A (en) | 2003-11-07 |
| MXPA03008403A (en) | 2004-01-29 |
| WO2002078620A3 (en) | 2003-04-17 |
| IL157358A0 (en) | 2004-02-19 |
| CZ20032540A3 (en) | 2004-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03007140A (en) | Chemical compounds. | |
| MXPA04008068A (en) | Method for administering glp-1 molecules. | |
| HK1080447A1 (en) | Retinol derivatives, their use in the treatment ofcancer and for potentiating the efficacy of other cytotoxic agents | |
| EE05074B1 (en) | Sulphonamide- and sulphamide-substituted imidazoquinolines, their use in therapy and pharmaceutical preparations containing them | |
| DK1689724T3 (en) | Quinazolinone compounds as anticancer agents | |
| SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
| ATE231872T1 (en) | THIAZOLOPYRIMIDE DERIVATIVES | |
| TR200100054T2 (en) | Paroxetine methanesulfonate | |
| DE60134274D1 (en) | Complex enthaltend modafinil und cyclodextrin | |
| MXPA97002401A (en) | Antiinflammatory agent for external use. | |
| MXPA04006572A (en) | Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections. | |
| DE60216233D1 (en) | Carbolinderivate | |
| HRP20050439B1 (en) | New use of dextran sulfate | |
| ATE319439T1 (en) | AGENTS FOR THE TREATMENT OF DISEASES OF THE TRACHEO-BRONCHIAL TRACT, IN PARTICULAR COPD | |
| IL175303A0 (en) | Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same | |
| MY137620A (en) | Therapeutic treatment | |
| HRP20070291T3 (en) | Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis | |
| DE69907926D1 (en) | 1,2,4-TRIAZOL-3-THION COMPOUNDS | |
| ATE417608T1 (en) | MEDICINAL COMPOSITIONS CONTAINING MODAFINIL COMPOUNDS | |
| WO2003008637A3 (en) | Use of genotyping in the individualization of therapy | |
| TW200640451A (en) | Use of estrogen receptor-β selective agonists for radiation- or chemotherapy-induced mucositis and radiation cystitis | |
| HUP0204208A2 (en) | Antipruritic agents for external use | |
| AU2003284885A8 (en) | Device and methods for sequential, regional delivery of multiple cytotoxic agents | |
| HUP0400255A2 (en) | Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | |
| AU2001285944A1 (en) | Fungicidal agent containing n-chlorotaurine and use thereof |